Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?
Key Points
Patent cliff concerns continue to weigh down Bristol Myers Squibb's stock.
The pharmaceutical company's management is taking active steps to counter some longstanding headwinds.
This is a great stock for income-focused investors, but it's also appealing to growth-minded investors.
- 10 stocks we like better than Bristol Myers Squibb ›
With a forward yield nearing 4%, Bristol Myers Squibb (NYSE: BMY) may seem like a great income buy among pharmaceutical stocks. Alongside a moderately high yield, this healthcare stock also has a nearly 20-year dividend growth track record, and trades at a low valuation.
Yet while at first glance Bristol Myers Squibb seems to check off all the right value and dividend boxes, it's worthwhile to give the pharmaceutical stock a closer examination, to look for any red flags. Specifically, any risk that this stock could become a "yield trap" for your portfolio.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images
The big reason behind Bristol Myers Squibb's high yield and low valuation
Bristol Myers Squibb stock has been on a tear, surging nearly 35% since September 2025. However, this latest wave of outperformance has come following an extended slump. This is a key reason why, even after the run-up, this stock appears very cheap, at just under 10 times forward earnings.
For most of this decade, shares have languished, largely due to a major patent cliff as several flagship drugs start to lose patent exclusivity. This includes the upcoming 2028 U.S. patent exclusivity losses for Eliquis and Opdivo. Having already experienced the loss of patent exclusivity for Eliquis in the European Union (EU) this year, analyst forecasts still call for earnings to drop from $6.95 to $6.56 per share next year. 2028 could bring more declines, as additional patents expire.
Why the patent cliff isn't a dealbreaker
Not only is the patent cliff a "known known." Management has already begun addressing it through cost-cutting measures and acquisitions. Rumors of a merger with AstraZeneca proved false, but a spate of smaller acquisitions in 2024 and 2025 leaves the company well-positioned in cardiovascular, immunology, and oncology.
Couple this with the stock's forward payout ratio of around 40%, and it's clear "yield trap fears" are overblown. The company appears well-positioned for a further comeback. Given the potential for further dividend growth and upside, Bristol Myers Squibb is a solid buy among healthcare stocks.
Should you buy stock in Bristol Myers Squibb right now?
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $417,413!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,341,294!*
Now, it’s worth noting Stock Advisor’s total average return is 950% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 13, 2026.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AstraZeneca Plc and Bristol Myers Squibb. The Motley Fool has a disclosure policy.
Recommended Articles
